Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Int230 symbols : Bmy save search
Intensity Therapeutics' Reports Up to 100% Tumor Necrosis After One Dose of Lead Asset, INT230-6 in Phase 2 INVINCIBLE Neoadjuvant Breast Cancer Study at the San Antonio Breast Cancer Symposium (SABCS)
Published: 2022-12-08 (Crawled : 13:00) - biospace.com/
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: 0.06%
H: 0.13%
C: -0.13%
int230 breast symposium one cancer study
Intensity Therapeutics Reports Use of INT230-6 Alone or in Combination with Ipilimumab Shows Evidence of Direct Tumor Necrosis
Published: 2022-11-18 (Crawled : 13:00) - biospace.com/
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: 0.48%
H: 0.79%
C: -0.1%
int230 therapeutics direct
Intensity Therapeutics Reports Use of INT230-6 Alone or in Combination with Ipilimumab Shows Evidence of Direct Tumor Necrosis and Promising Overall Survival Results in Adult Subjects with Metastatic Sarcomas at the Connective Tissue Oncology Society (CTOS) 2022
Published: 2022-11-18 (Crawled : 12:20) - prnewswire.com
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: 0.48%
H: 0.79%
C: -0.1%
int230 therapeutics direct results
Intensity Therapeutics' INT230-6 Data will be presented at the 2022 Society for Immunotherapy of Cancer Meeting
Published: 2022-11-11 (Crawled : 13:00) - biospace.com/
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: -1.61%
H: 0.45%
C: -2.74%
int230 immunotherapy meeting cancer
Intensity Therapeutics' INT230-6 Demonstrates Increased Survival as Either Monotherapy or in Combination with Pembrolizumab in Patients with Relapsed, Refractory, Metastatic Solid Tumor Cancers
Published: 2022-11-11 (Crawled : 12:20) - prnewswire.com
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: -1.61%
H: 0.45%
C: -2.74%
int230
Intensity Therapeutics' Data on Lead Asset, INT230-6, Accepted for Three Presentations at Key Upcoming Clinical Oncology Conferences in November
Published: 2022-11-01 (Crawled : 12:20) - prnewswire.com
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: -0.61%
H: 1.02%
C: 0.91%
int230
Intensity Therapeutics' INT230-6 Demonstrates Increased Survival as Either Monotherapy or in Combination with Ipilimumab in Patients with Relapsed, Refractory, Metastatic Sarcomas
Published: 2022-06-02 (Crawled : 11:00) - prnewswire.com
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: 0.21%
H: 0.0%
C: 0.0%
int230
Intensity Therapeutics Announces New Clinical Data in Solid Tumors for its Lead Asset, INT230-6
Published: 2022-05-03 (Crawled : 00:00) - biospace.com/
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: 0.36%
H: 0.0%
C: 0.0%
int230 therapeutics
Intensity Therapeutics Reports Promising Early Efficacy Results Using INT230-6 as a Monotherapy or in Combination with Pembrolizumab in Metastatic Breast Cancer at the 2021 San Antonio Breast Cancer Symposium®
Published: 2021-12-10 (Crawled : 14:30) - biospace.com/
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
int230 symposium therapeutics therapy results cancer breast cancer metastatic breast cancer
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.